Stoke Therapeutics (STOK) CMO Ticho Barry Sells 4,767 Shares

What Happened

• Ticho Barry, Chief Medical Officer of Stoke Therapeutics (STOK), had performance stock units convert to common shares and then sold shares. On Aug 14, 2026, 10,000 performance stock units converted to 10,000 shares (reported as exercise/conversion at $0.00). An issuer‑mandated sale to satisfy tax withholding related to the vesting/settlement is reported. On Aug 18, 2026, Barry sold a total of 4,767 shares in open‑market transactions for combined proceeds of $152,690 (4,525 shares at a weighted avg $32.01 = $144,833; 242 shares at a weighted avg $32.47 = $7,857).

Key Details

• Transaction dates & prices:
  • Aug 14, 2026: Conversion/exercise of 10,000 performance stock units into 10,000 shares (acquired at $0.00).
  • Aug 14, 2026: 10,000 shares reported disposed (issuer‑mandated sale to cover tax withholding related to vesting) — see footnote.
  • Aug 18, 2026: Open market sales of 4,525 shares at a weighted avg $32.01 (range $31.40–$32.36) and 242 shares at a weighted avg $32.47 (range $32.44–$32.54).
• Total proceeds from the Aug 18 sales: $152,690.
• Shares owned after the transactions: not specified in the provided filing excerpts.
• Notable footnotes:
  • F1: Issuer‑mandated sale to satisfy tax withholding on vesting/settlement.
  • F4/F5: Each performance stock unit equals one share; achievement certified Aug 14, 2025 with half vested then and the remainder vesting Aug 14, 2026 (subject to continued service).
  • F2/F3: Reported sale prices are weighted averages; individual trade prices fall within specified ranges.
• Filing timeliness: Form filed Aug 18, 2026 covering events of Aug 14 and Aug 18; no late‑filing flag indicated in the provided data.

Context

• These filings show a settlement of performance stock units (conversion into shares) and sales that include issuer‑mandated withholding to cover taxes. The open‑market sales on Aug 18 reduced holdings and generated ~$152.7K in proceeds; such sales are often routine for tax or diversification purposes. No inference about insider sentiment should be drawn solely from this activity.